A Phase 3 interventional study of CD07805/47 Gel 0.5% and CD07805/47 Gel Placebo in Erythema, sponsored by Galderma R&D. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-11-06.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare the efficacy and assess the safety of CD07805/47 gel 0.5% applied topically once daily for 29 days versus vehicle control, in subjects with moderate to severe chronic persistent vascular facial erythema
131 studies on the registry are indexed under Erythema; 17 are open to participants now.
Browse Erythema studies →Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
active arm
Drug: CD07805/47 Gel 0.5%
Comparator arm
Drug: CD07805/47 Gel Placebo
Drug page: Brimonidine
Composite success on both CEA (Clinician Erythema Assessment ) and PSA (Patient Self Assessment)
2-grade improvement on both CEA and PSA at Hours 3, and 6 after Pre-dose (T0)on Day 29
Time frame: Day 29
Composite improvement on both CEA (Clinician Erythema Assessment ) and PSA (Patient Self Assessment)
1-grade improvement on both CEA and PSA at 30 minutes after pre-dose (T0) on Day 1
Time frame: Day 1
No study locations are listed for this record.
This study is withdrawn, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brimonidine